These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1008 related articles for article (PubMed ID: 18228189)

  • 1. [Bladder preservation or initial cystectomy in T1G3 bladder cancer: which parameters help in therapeutic decision-making?].
    Denzinger S; Burger M; Fritsche HM; Ganzer R; Blana A; Wieland WF; Otto W
    Aktuelle Urol; 2008 Jan; 39(1):58-61; discussion 62-3. PubMed ID: 18228189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach?
    Denzinger S; Fritsche HM; Otto W; Blana A; Wieland WF; Burger M
    Eur Urol; 2008 Jan; 53(1):146-52. PubMed ID: 17624657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bladder sparing approach for initial T1G3 bladder cancer: Do multifocality, size of tumor or concomitant carcinoma in situ matter? A long-term analysis of 132 patients.
    Denzinger S; Otto W; Fritsche HM; Roessler W; Wieland WF; Hartmann A; Burger M
    Int J Urol; 2007 Nov; 14(11):995-9; discussion 999. PubMed ID: 17956523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Results of radical cystectomy for management of invasive bladder cancer with special reference to prognostic factors and quality of life depending on the type of urinary diversion].
    Słojewski M
    Ann Acad Med Stetin; 2000; 46():217-29. PubMed ID: 11712306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recurrence and progression of T1G3 transitional cell carcinoma of the bladder treated with intravesical bacillus Calmette-Guérin.
    Günlüsoy B; Değirmenci T; Arslan M; Nergiz N; Minareci S; Ayder AR
    Urol Int; 2005; 75(2):107-13. PubMed ID: 16123562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Initial conservative treatment for grade 3 Ta-1 superficial bladder cancer].
    Fujimoto K; Chihara Y; Kondo H; Hirao Y
    Hinyokika Kiyo; 2006 Jun; 52(6):433-8. PubMed ID: 16848356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour.
    Solsona E; Iborra I; Rubio J; Casanova J; Almenar S
    BJU Int; 2004 Dec; 94(9):1258-62. PubMed ID: 15610101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival rates after radical cystectomy according to tumor stage of bladder carcinoma at first presentation.
    May M; Helke C; Nitzke T; Vogler H; Hoschke B
    Urol Int; 2004; 72(2):103-11. PubMed ID: 14963349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.
    Huguet J; Crego M; Sabaté S; Salvador J; Palou J; Villavicencio H
    Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary T1G3 bladder cancer: organ preserving approach or immediate cystectomy?
    Thalmann GN; Markwalder R; Shahin O; Burkhard FC; Hochreiter WW; Studer UE
    J Urol; 2004 Jul; 172(1):70-5. PubMed ID: 15201740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for positive findings in patients with high-grade T1 bladder cancer treated with transurethral resection of bladder tumour (TUR) and bacille Calmette-Guérin therapy and the decision for a repeat TUR.
    Orsola A; Cecchini L; Raventós CX; Trilla E; Planas J; Landolfi S; de Torres I; Morote J
    BJU Int; 2010 Jan; 105(2):202-7. PubMed ID: 19558557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy?
    Weiss C; Wolze C; Engehausen DG; Ott OJ; Krause FS; Schrott KM; Dunst J; Sauer R; Rödel C
    J Clin Oncol; 2006 May; 24(15):2318-24. PubMed ID: 16710030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can patient selection for bladder preservation be based on response to chemotherapy?
    Sternberg CN; Pansadoro V; Calabrò F; Schnetzer S; Giannarelli D; Emiliozzi P; De Paula F; Scarpone P; De Carli P; Pizzo M; Platania A; Amini M
    Cancer; 2003 Apr; 97(7):1644-52. PubMed ID: 12655521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TUR and adjuvant intravesical chemotherapy in T1G3 bladder tumors: recurrence, progression and survival in 137 selected patients followed up to 20 years.
    Serretta V; Pavone C; Ingargiola GB; Daricello G; Allegro R; Pavone-Macaluso M
    Eur Urol; 2004 Jun; 45(6):730-5; discussion 735-6. PubMed ID: 15149744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary invasive versus progressive invasive transitional cell bladder cancer: multicentric study of overall survival rate.
    Ferreira U; Matheus WE; Nardi Pedro R; Levi D'Ancona CA; Reis LO; Stopiglia RM; Denardi F; Rodrigues Netto N; de Cássio Zequi S; da Fonseca FP; Lopes A; Cardoso Guimarães G; de Carvalho Fernandes R; Cardenuto Perez MD
    Urol Int; 2007; 79(3):200-3. PubMed ID: 17940350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Twelve-year follow up of a randomized prospective trial comparing bacillus Calmette-Guerin and epirubicin as adjuvant therapy in superficial bladder cancer.
    Cheng CW; Chan SF; Chan LW; Chan CK; Ng CF; Cheung HY; Chan SY; Wong WS; Lai FM; To KF; Li ML
    Int J Urol; 2005 May; 12(5):449-55. PubMed ID: 15948743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of histopathological tumour growth patterns at the invasion front of T1G3 urothelial carcinoma of the bladder.
    Denzinger S; Burger M; Fritsche HM; Bertz S; Hofstädter F; Wieland WF; Hartmann A; Otto W
    Scand J Urol Nephrol; 2009; 43(4):282-7. PubMed ID: 19382004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.
    Lerner SP; Tangen CM; Sucharew H; Wood D; Crawford ED
    J Urol; 2007 May; 177(5):1727-31. PubMed ID: 17437798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radical cystectomy after bacillus Calmette-Guérin for high-risk Ta, T1, and carcinoma in situ: defining the risk of initial bladder preservation.
    Nieder AM; Simon MA; Kim SS; Manoharan M; Soloway MS
    Urology; 2006 Apr; 67(4):737-41. PubMed ID: 16618564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes following radical cystectomy for primary nontransitional cell carcinoma of the bladder compared to transitional cell carcinoma of the bladder.
    Rogers CG; Palapattu GS; Shariat SF; Karakiewicz PI; Bastian PJ; Lotan Y; Gupta A; Vazina A; Gilad A; Sagalowsky AI; Lerner SP; Schoenberg MP
    J Urol; 2006 Jun; 175(6):2048-53; discussion 2053. PubMed ID: 16697800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.